IDEXX Laboratories, Inc. $IDXX Stock Holdings Increased by Public Employees Retirement System of Ohio

Key Points

• The Public Employees Retirement System of Ohio increased its holdings in IDEXX Laboratories, Inc. by 3.9% in the second quarter, owning 27,716 shares valued at approximately $14.87 million.
• CEO Jonathan Jay Mazelsky sold 29,260 shares in early August, representing a 25.99% decrease in his position, while other executives also sold a substantial amount of stock.
• Analysts are optimistic about IDEXX Laboratories, with several raising their price targets, including Morgan Stanley's increase to $765.00 and a consensus target price of $649.44 reflecting a Moderate Buy rating.

Public Employees Retirement System of Ohio boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 3.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,716 shares of the company's stock after buying an additional 1,041 shares during the quarter. Public Employees Retirement System of Ohio's holdings in IDEXX Laboratories were worth $14,865,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Mutual of America Capital Management LLC raised its position in shares of IDEXX Laboratories by 79.6% during the 1st quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company's stock worth $8,160,000 after purchasing an additional 8,609 shares during the period. Golden State Wealth Management LLC raised its position in shares of IDEXX Laboratories by 3,766.7% during the 1st quarter. Golden State Wealth Management LLC now owns 116 shares of the company's stock worth $49,000 after purchasing an additional 113 shares during the period. Plato Investment Management Ltd raised its position in shares of IDEXX Laboratories by 37.1% during the 1st quarter. Plato Investment Management Ltd now owns 3,087 shares of the company's stock worth $1,310,000 after purchasing an additional 835 shares during the period. Sagespring Wealth Partners LLC acquired a new stake in shares of IDEXX Laboratories during the 1st quarter worth approximately $229,000. Finally, Inspire Investing LLC raised its position in shares of IDEXX Laboratories by 34.4% during the 1st quarter. Inspire Investing LLC now owns 13,577 shares of the company's stock worth $5,702,000 after purchasing an additional 3,472 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at IDEXX Laboratories

In other news, CEO Jonathan Jay Mazelsky sold 29,260 shares of IDEXX Laboratories stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the transaction, the chief executive officer directly owned 83,311 shares in the company, valued at approximately $52,650,885.78. This trade represents a 25.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sharon E. Underberg sold 5,450 shares of IDEXX Laboratories stock in a transaction on Friday, August 8th. The shares were sold at an average price of $651.60, for a total value of $3,551,220.00. Following the transaction, the executive vice president owned 6,156 shares in the company, valued at approximately $4,011,249.60. This trade represents a 46.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 54,057 shares of company stock worth $34,293,468 in the last quarter. Company insiders own 0.98% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Morgan Stanley increased their price target on IDEXX Laboratories from $722.00 to $765.00 and gave the stock an "overweight" rating in a research report on Friday, August 15th. Wall Street Zen upgraded IDEXX Laboratories from a "buy" rating to a "strong-buy" rating in a research report on Saturday, September 20th. Leerink Partners increased their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. BTIG Research raised their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a research report on Tuesday, August 5th. Finally, JPMorgan Chase & Co. raised their target price on IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a research report on Monday, August 4th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $649.44.

IDEXX Laboratories Stock Up 2.3%

IDXX opened at $632.22 on Friday. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $688.12. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The stock has a market cap of $50.58 billion, a P/E ratio of 52.64, a P/E/G ratio of 4.00 and a beta of 1.56. The stock's 50 day moving average price is $625.60 and its 200 day moving average price is $527.35.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion for the quarter, compared to analysts' expectations of $1.06 billion. During the same period last year, the firm earned $2.44 EPS. The firm's revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.